Are you ready to take TACE to the next level?

TACE is standard of care in the BCLC guidelines for HCC, and we recognise that there is still scope for improvement, for example complete response rates, duration of response, leading to the need for retreatment.

As Terumo we are proud that we have generated in recent years a large set of clinical data leading to a new concept of advanced TACE. Several recent clinical publications using the Terumo portfolio have shown new evidence to further improve TACE.

This evidence could further strengthen the case for TACE at the oncological tumour board.

Clinical Data

The latest clinical evidence with the Terumo portfolio in DEM-TACE and Occlusafe-TACE brings new perspectives on the future of TACE treatment:

A meta-analysis from over 550 patients with HCC treated with DEM-TACE will support your practice of DEM-TACE in tumour board discussions. This data was also presented in major oncological congresses, including ESMO GI 2020 and ASCO GI 2021

Occlusafe-TACE combination data demonstrate significantly fewer retreatment for effective disease control within the first 6 months of follow up, vs TACE alone which may offer prolonged patient survival due to lower liver toxicity.

Learn more about Advanced TACE clinical data

Taking TACE to the next level

Our ultimate goal by taking TACE to the next level: to Prolong HCC patients Life expectancy

Improving complete response rates and maintaining this response lead to an increase in overall survival¹

DEM-TACE treatments reach high complete response rates:¹

60% Complete response rate leading to almost 3 years overall survival (35.8month) (n=586 patients)¹

Even when multiple treatments are required for larger , complex tumours²

20% of patients achieved complete response after 3rd or 4th TACE procedures (n=97)²

References:

De Baere T et al. Presented at ESMO GI 2020 (pooled analyses)
de Baere T et al. Cancers (Basel) 2020;12:E3405 (PARIS registry)

Breaking new data with Advanced TACE

Watch the videos below - which are of presentations from ECIO 2021.

What the evidence says

Discover our clinical evidence and case studies concerning this topic.

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial micro balloon catheter for hepatocellular carcinoma: Technical and safety considerations

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Balloon-Occluded Transarterial Chemoembolization: In which size range does it perform best? A comparison of its efficacy versus conventional Transarterial Chemoembolization, using Propensity score matching

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma

Giammaria Fiorentini, Donatella Sarti, Riccardo Carandina, Luca Mulazzani, Cinzia Mincarelli, Roberto Candelari, Renato Argirò, Caterina Fiorentini & Camillo Aliberti

Featured product: LifePearl™ Drug Elutable Microspheres

Advanced TACE Programme Studies

Featured products: LifePearl™ Drug Elutable Microspheres, Occlusafe™ Temporary Occlusion Balloon Catheter

Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes

Gontran Verset et al. Hepatic Oncology(2020)

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

Pierleone Lucatelli et al. CVIR(2019)

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis

Rita Golfieri et al. CVIR(2021)

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Safety, tolerability, and efficacy of transarterial chemoembolization using anthracyclines-loaded drug-eluting microspheres for treatment of patients with unresectable hepatocellular carcinoma: Pooled analyses

T De Baere et al Annals of oncology (2020) VOLUME 31, SUPPLEMENT 3, S220, JULY 01

Featured product: LifePearl™ Drug Elutable Microspheres

The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolization in Colorectal Cancer Liver Metastases: Interim Analysis

Philippe L. Pereira et al Cardiovasc Intervent Radiol (2020) https://doi.org/10.1007/s00270-020-02646-8

Featured product: LifePearl™ Drug Elutable Microspheres

First Usage of Combined HCC Treatment with Balloon-Occluded TACE and MW Ablation

Featured products: Occlusafe™ Temporary Occlusion Balloon Catheter, LifePearl™ Drug Elutable Microspheres

Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients

Filipe Veloso Gomes et al, J Vasc Interv Radiol (2018):1–9 DOI: https://doi.org/10.1016/j.jvir.2018.02.004

Featured product: LifePearl™ Drug Elutable Microspheres

Chemoembolization Alone or Associated with Bevacizumab for Therapy of Colorectal Cancer Metastases: Preliminary Results of a Randomized Study

Giammaria Fiorentini et al in vivo (2020) 34: 683-686 DOI:10.21873/invivo.11824

Featured product: LifePearl™ Drug Elutable Microspheres

LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study

Geert Maleux et al Anti-Cancer Drugs (2020) Nov; 31(10):1084-1090. doi:10.1097/CAD.0000000000000980.

Featured product: LifePearl™ Drug Elutable Microspheres

Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards

Pierleone Lucatelli et al J Vasc Interv Radiol (2019):1–9 DOI: https://doi.org/10.1016/j.jvir.2018.10.026

Featured product: LifePearl™ Drug Elutable Microspheres

Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer

Giammaria Fiorentini et al World J Gastrointest Oncol (2017); 9(9): 379-384 DOI: 10.4251/wjgo.v9.i9.379

Featured product: LifePearl™ Drug Elutable Microspheres

Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry

T De Baere et al. Cancers (2020), 12, 3405; doi:10.3390/cancers12113405

Featured product: LifePearl™ Drug Elutable Microspheres

Balloon-Occluded Transcatheter Arterial Chemoembolization (b- TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Microballoon-related interventions in various endovascular treatments of body trunk lesions

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super-selective TACE

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Efﬁcacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results

Masahiro Ogawa, Kentaro Takayasu, Midori Hirayama, Takao Miura, Katsuhiko Shiozawa, Masahisa Abe, Naoki Matsumoto, Hiroshi Nakagawara, Shu Ohshiro, Toshiki Yamamoto, Naohide Tanaka, Mitsuhiko Moriyama, Haruomi Mutou, Yoshinobu Yamamoto and Toshiyuki Irie

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

LifePearl® loaded with doxorubicin - downstage a patient with HCC to reach liver transplant

Featured product: LifePearl™ Drug Elutable Microspheres

SIRT with Occlusafe in unresectable HCC, portal vein thrombosis and high-flow fistula

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Y90 SIRT with Occlusafe® Micro-Balloon Catheter infusion system in a patient with unresectable HCC: the right way

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon- occluded Arterial Stump Pressure

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

Safety and efﬁcacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma

Featured product: Occlusafe™ Temporary Occlusion Balloon Catheter

See all clinical evidence

Upcoming events

Mauris sed purus volutpat, convallis nibh ac, feugiat lorem. Sed dignissim arcu eulala.

ECIO 2023

April 16 - 19

Details

All events

Do you need more info about this product?

Our sales representatives are here for you.

Send us a message

First name *

Last name *

Function

Company *

Country *

E-mail address *

Question *

I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*

I wish to receive information and marketing updates from Terumo.

* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public

For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.

This site uses cookies to improve your user experience.

This site uses cookies. Functional cookies are necessary for the use of this website and cannot be refused. Other cookies are only placed if you choose to do so. For further information please read our cookies notice.

This site uses cookies. Functional cookies are necessary for the use of this ... website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.

Advanced TACE

Are you ready to take TACE to the next level?

Clinical Data

Taking TACE to the next level

Taking TACE to the next level

Breaking new data with Advanced TACE

What the evidence says

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial micro balloon catheter for hepatocellular carcinoma: Technical and safety considerations

Balloon-Occluded Transarterial Chemoembolization: In which size range does it perform best? A comparison of its efficacy versus conventional Transarterial Chemoembolization, using Propensity score matching

A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma

​Giammaria Fiorentini, Donatella Sarti, Riccardo Carandina, Luca Mulazzani, Cinzia Mincarelli, Roberto Candelari, Renato Argirò, Caterina Fiorentini & Camillo Aliberti

Advanced TACE Programme Studies

Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes

Gontran Verset et al. Hepatic Oncology(2020)

Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

​Pierleone Lucatelli et al. CVIR(2019)

Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis

​Rita Golfieri et al. CVIR(2021)

Safety, tolerability, and efficacy of transarterial chemoembolization using anthracyclines-loaded drug-eluting microspheres for treatment of patients with unresectable hepatocellular carcinoma: Pooled analyses

​T De Baere et al Annals of oncology (2020) VOLUME 31, SUPPLEMENT 3, S220, JULY 01

The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolization in Colorectal Cancer Liver Metastases: Interim Analysis

​Philippe L. Pereira et al Cardiovasc Intervent Radiol (2020) https://doi.org/10.1007/s00270-020-02646-8

First Usage of Combined HCC Treatment with Balloon-Occluded TACE and MW Ablation

Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients

​Filipe Veloso Gomes et al, J Vasc Interv Radiol (2018):1–9 DOI: https://doi.org/10.1016/j.jvir.2018.02.004

Chemoembolization Alone or Associated with Bevacizumab for Therapy of Colorectal Cancer Metastases: Preliminary Results of a Randomized Study

​Giammaria Fiorentini et al in vivo (2020) 34: 683-686 DOI:10.21873/invivo.11824

LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study

​Geert Maleux et al Anti-Cancer Drugs (2020) Nov; 31(10):1084-1090. doi:10.1097/CAD.0000000000000980.

Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards

​Pierleone Lucatelli et al J Vasc Interv Radiol (2019):1–9 DOI: https://doi.org/10.1016/j.jvir.2018.10.026

Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer

​Giammaria Fiorentini et al World J Gastrointest Oncol (2017); 9(9): 379-384 DOI: 10.4251/wjgo.v9.i9.379

Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry

​T De Baere et al. Cancers (2020), 12, 3405; doi:10.3390/cancers12113405

Balloon-Occluded Transcatheter Arterial Chemoembolization (b- TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma

Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study

Microballoon-related interventions in various endovascular treatments of body trunk lesions

Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma

Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super-selective TACE

Efﬁcacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results

​Masahiro Ogawa, Kentaro Takayasu, Midori Hirayama, Takao Miura, Katsuhiko Shiozawa, Masahisa Abe, Naoki Matsumoto, Hiroshi Nakagawara, Shu Ohshiro, Toshiki Yamamoto, Naohide Tanaka, Mitsuhiko Moriyama, Haruomi Mutou, Yoshinobu Yamamoto and Toshiyuki Irie

LifePearl® loaded with doxorubicin - downstage a patient with HCC to reach liver transplant

Lifepearl loaded with doxorubicin in a patient with HCC pre-transplant

Balloon-Occluded DEB-TACE for a single node HCC as bridge to transplantation

Successful Balloon-Occluded DEB-TACE after failure of SIRT and DEB-TACE

SIRT with Occlusafe in unresectable HCC, portal vein thrombosis and high-flow fistula

Y90 SIRT with Occlusafe® Micro-Balloon Catheter infusion system in a patient with unresectable HCC: the right way

Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization

Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon- occluded Arterial Stump Pressure

Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations

Safety and efﬁcacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma

Upcoming events

ECIO 2023

April 16 - 19

Do you need more info about this product?

Send us a message

This site uses cookies to improve your user experience.

Giammaria Fiorentini, Donatella Sarti, Riccardo Carandina, Luca Mulazzani, Cinzia Mincarelli, Roberto Candelari, Renato Argirò, Caterina Fiorentini & Camillo Aliberti

Pierleone Lucatelli et al. CVIR(2019)

Rita Golfieri et al. CVIR(2021)

T De Baere et al Annals of oncology (2020) VOLUME 31, SUPPLEMENT 3, S220, JULY 01

Philippe L. Pereira et al Cardiovasc Intervent Radiol (2020) https://doi.org/10.1007/s00270-020-02646-8

Filipe Veloso Gomes et al, J Vasc Interv Radiol (2018):1–9 DOI: https://doi.org/10.1016/j.jvir.2018.02.004

Giammaria Fiorentini et al in vivo (2020) 34: 683-686 DOI:10.21873/invivo.11824

Geert Maleux et al Anti-Cancer Drugs (2020) Nov; 31(10):1084-1090. doi:10.1097/CAD.0000000000000980.

Pierleone Lucatelli et al J Vasc Interv Radiol (2019):1–9 DOI: https://doi.org/10.1016/j.jvir.2018.10.026

Giammaria Fiorentini et al World J Gastrointest Oncol (2017); 9(9): 379-384 DOI: 10.4251/wjgo.v9.i9.379

T De Baere et al. Cancers (2020), 12, 3405; doi:10.3390/cancers12113405

Masahiro Ogawa, Kentaro Takayasu, Midori Hirayama, Takao Miura, Katsuhiko Shiozawa, Masahisa Abe, Naoki Matsumoto, Hiroshi Nakagawara, Shu Ohshiro, Toshiki Yamamoto, Naohide Tanaka, Mitsuhiko Moriyama, Haruomi Mutou, Yoshinobu Yamamoto and Toshiyuki Irie